Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Pollack

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Circulation|September 13, 2017
Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban)Pierre Deharo, Gregory Ducrocq, Christoph Bode, et al.
Critical Pathways in Cardiology|May 16, 2014
Emergency department patients with acute severe hypertension: a comparison of those admitted versus discharged in studying the treatment of acute hypertension registryKurt Kleinschmidt, Phillip Levy, Allison Wyman, et al.
JAMA|December 29, 2005
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromesKaren P Alexander, Anita Y Chen, Matthew T Roe, et al.
Circulation. Cardiovascular Interventions|June 14, 2018
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.
Circulation. Cardiovascular Interventions|January 12, 2021
Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.
The American Journal of Cardiology|September 10, 2013
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial)Jean-Philippe Collet, Kurt Huber, Marc Cohen, et al.
American Heart Journal|September 29, 2009
Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registryJason N Katz, Joel M Gore, Alpesh Amin, et al.
Lancet (London, England)|August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialGilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Circulation|September 13, 2017
Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban)Pierre Deharo, Gregory Ducrocq, Christoph Bode, et al.
Critical Pathways in Cardiology|May 16, 2014
Emergency department patients with acute severe hypertension: a comparison of those admitted versus discharged in studying the treatment of acute hypertension registryKurt Kleinschmidt, Phillip Levy, Allison Wyman, et al.
JAMA|December 29, 2005
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromesKaren P Alexander, Anita Y Chen, Matthew T Roe, et al.
Circulation. Cardiovascular Interventions|June 14, 2018
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.
Circulation. Cardiovascular Interventions|January 12, 2021
Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.
The American Journal of Cardiology|September 10, 2013
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial)Jean-Philippe Collet, Kurt Huber, Marc Cohen, et al.
American Heart Journal|September 29, 2009
Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registryJason N Katz, Joel M Gore, Alpesh Amin, et al.
Lancet (London, England)|August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialGilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
Pageof 3